Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05943457

Vitamin K2 Supplementation in Adult Episodic Migraine

Efficacy of Vitamin K2 Supplementation in Adult Episodic Migraine

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
160 (estimated)
Sponsor
Sola Aoun Bahous, M.D. Ph.D. · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Migraine is a debilitating illness and a major cause of disability in the world. It is highly prevalent, especially among women. Vitamin supplementation is a potential therapeutic option for migraines that remains largely under-explored. Several studies have shown that people with migraine tend to have higher arterial stiffness than people without migraine. Vitamin K2 deficiency is an important mediator of arterial stiffness and calcification due to decreased carboxylation of matrix Gla protein (MGP). Supplementation reverses these changes and improves vascular health in patients with end stage renal disease according to previous studies. Therefore, vitamin K2 supplementation could serve a potential role in migraine patients. The purpose of the study is to test the effect of vitamin K2 on decreasing the frequency of migraine attacks and decreasing arterial stiffness. The population will be recruited from the neurology clinic at LAU Medical Center-Rizk Hospital and will constitute of adult patients. They will be randomized to receive either the supplement of vitamin K2 or a placebo for the duration of 6 months. Laboratory tests and arterial stiffness measurements will be done at the beginning, middle, and at the end of the study for comparison.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTVitamin K2 or menaquinone-7Vitamin K2 (MK7) 360 mcg/day orally once daily for 6 months
OTHERPlaceboPlacebo pills will be administered orally once daily for 6 months

Timeline

Start date
2024-03-06
Primary completion
2026-09-01
Completion
2026-12-01
First posted
2023-07-13
Last updated
2025-11-18

Locations

1 site across 1 country: Lebanon

Source: ClinicalTrials.gov record NCT05943457. Inclusion in this directory is not an endorsement.